KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with ...

New data reveals that Januvia was as effective as Glucotrol in reducing blood sugar levels in patients with type 2 diabetes.Merck (NYSE: MRK) announced today its drug Januvia was as effective as the ...

(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a ...

Patients treated with ITCA 650 60mcg experienced superior reductions in HbA1c versus those treated with Januvia® (sitagliptin) 100mg (-1.5% versus -0.8%; p<0.001) ITCA 650 60mcg produced significantly ...

The ITCA 650 device, which delivers tiny doses of exenatide, could be a game changer in solving the problem of medication adherence. An application for FDA approval is expected in the first half of ...

In a phase 3 trial of patients with type 2 diabetes not controlled with metformin plus sulfonylurea, adding canagliflozin (Invokana, Janssen Pharmaceuticals) improved glycemic control better than ...

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. AMLN will be presenting at the Piper Jaffray Europe Conference in London on Wednesday, June 24, 2009 at 10:30 a.m ...

Co says data presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrated that, when used investigationally as initial therapy in combination with metformin, ...

Diabetics gained a new way of controlling their blood sugar levels Tuesday with the federal approval of a novel pill for Type 2 diabetes, which affects about 20 million Americans. The Food and Drug ...

Merck, known as MSD outside the United States and Canada, announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled study of the ...

MSD, known as Merck in the United States and Canada, recently announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled study of the ...